• Mohawk Group Holdings Inc. designs, develops, markets, and sells consumer products guided by machine learning, natural language processing, and data analytics
• Mohawk is on a mission to become the leading e-commerce consumer brands platform
• The company’s acquisition of Healing Solutions, LLC, itself a leading online seller, heralded Mohawk’s entry into the essential oils sector
• The acquisition is the latest in a string of similar business moves and is expected to increase MWK’s revenue for the 2021 financial year

Mohawk Group Holdings (NASDAQ: MWK), a growing tech-enabled consumer products company, has continued its quest to become the leading e-commerce consumer brands platform with its latest acquisition of Healing Solutions, LLC. MWK paid approximately $15.3 million in cash in addition to issuing approximately 1.4 million shares of Mohawk’s common stock. On its own, MWK has launched consumer products across four brands, spanning home and kitchen, beauty, consumer electronics, and appliances. Thus, the acquisition heralded its entry into the essential oils’ category.

Healing Solutions is a leading online seller of essential oils whose unaudited trailing-twelve-month revenue and operating income (excluding inventory liquidations) as of October 31, 2020, were approximately $65.2 million and $12.7 million, respectively. Notably, MWK paid an amount equivalent to about 3.8 times Healing Solutions’ trailing-twelve-month operating income. This amount excludes additional considerations in the form of shares allocated towards acquiring the e-commerce platform’s inventory. MWK issued 170,000 shares of its common stock for this purpose, subject to adjustments that would not go beyond 280,000 shares.

The acquisition is expected to bump MWK’s revenue upwards, as indicated by Mohawk’s adjusted outlook for the financial year 2021. MWK expects a net revenue ranging between $340 million and $370 million, up from a range of $290 million to $320 million. The Company guided 2021 Adjusted EBITDA to $28 million to $32 million. It also estimates its net income will range between $1 million and $5 million for the period ending December 31, 2021.

Healing Solutions is the latest in a string of acquisitions, which Yaniv Sarig – Mohawk Group Holdings Inc.’s co-founder and chief executive officer – hails as a step forward in the company’s mission to build the leading e-commerce consumer brands platform. “We are thrilled to enter the essential oils category, which further diversifies our e-commerce portfolio of brands. Consumable products with recurring purchases and subscription revenue opportunities that complement our hard goods brands have been on our radar.” Yaniv stated in a news release announcing the acquisition (https://ibn.fm/pYysW).

Yaniv regarded the calculated strategy “to create a supply chain and technology platform designed to operate e-commerce brands across a wide spectrum of categories at scale” as one that was continuing to bear fruit. In late 2020, MWK announced the accretive acquisition of four e-commerce brands, namely Pohl and Schmitt, Spiralizer, Mueller, and Pursteam, adding 43 new products to its portfolio (https://ibn.fm/vzT8w).

Although the CEO claimed that the company was still in the early stages of executing its ambitious goals of becoming a market leader, Mohawk Group Holdings Inc. looks poised to achieve them sooner rather than later.

For more information on Mohawk Group Holdings Inc., visit the company’s website at https://mohawkgp.com/.

In addition, the company has announced a live interview with Mohawk Group Co-Founder & CEO Yaniv Sarig (https://ibn.fm/pz2Vu).

NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK

• Frequent, COVID-19 rapid tests could spur end of pandemic, make stay-at-home orders possible
• Countries turning to faster, more affordable tests to curb virus spread, enable economic recovery
• United Medical poised to capitalize on surging demand for rapid testing

Frequent rapid testing could curb COVID-19 within weeks, a recent study published by the University of Colorado Boulder and Harvard University shows (https://ibn.fm/qmy42). Factors such as test turnaround-time and frequency are key in limiting the spread of the virus, making rapid tests one of the key tools for managing the virus outbreak. As such, the rapid tests are increasingly used in countries around the world to enable economic revival and help societies go back to normal. United Medical Equipment Business Solutions Network (“UME”), a company offering both antigen and antibody rapid COVID-19 test kits, stands ready to respond to the growing need for this critical public health tool. The study demonstrates that testing half of the population weekly with inexpensive, rapid-turnaround COVID-19 tests could accelerate virus elimination within weeks. Despite their lower sensitivity compared to gold-standard clinical tests, these rapid kits could enable an approach based on “personalized stay-at-home orders,” which would remove the need for mass closures of hospitality outlets, retail stores and schools, the study notes. For example, in a hypothetical scenario involving a city with 4% of individuals already infected, rapid testing three out of four people every three days would reduce the number ultimately infected by as much as 88%. This would be sufficient to push the epidemic toward extinction within six weeks, authors claim. The research was published against the backdrop of significant commercial and academic effort to develop low-cost, rapid tests that could be deployed in large public settings or commercialized for do-it-yourself use. These tests could enable the comeback of public events, such as sports competitions, concerts and travel, which are currently almost completely shut down because of their high risk of virus spread. Combined with the use of masks, rapid testing of people involved in these activities could bring back to life almost-decimated sectors while minimizing the spread risk at the same time. Several countries have already begun countrywide testing, while the new U.S. administration has named rapid testing as a priority. As the countries are turning to faster, cheaper tests to accelerate the COVID-19 public health response, demand for these products is growing. As a supplier of rapid COVID-19 test kits, United Medical is poised to capitalize on the surging need for rapid testing. Designed to test workers without symptoms as well as those who show certain symptoms or have been in close contact with someone who has been infected, these test kits could be the answer to large-scale testing needs in the future. Capable of quickly and affordably identifying individuals who are most likely to be actively infectious, these products will continue to be a valuable addition to the tool kit in the fight against COVID-19. Testing is most likely to remain an important part of health protocols even after the widespread rollout of the vaccines, securing the sizeable market for rapid testing kits in the future. For more information about United Medical as well as its Medication Management app, visit the www.UnitedMedSolutions.com and www.MedicationManagement.app. NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• UltraPlay provides turn-key platform to reach growing global audience.
• Esports is now a necessity for gambling operators.
• Success in eSports lies in ability to pivot, continually improve player experience, and build brand loyalty.

Mobius Interactive, an online gaming operator, has partnered with the multi award-winning betting provider UltraPlay (https://ibn.fm/dzMDK). This partnership equips Mobius to provide players with access to more than 34 eSports games, live events and mystery jackpots, as well as live and prematch odds. In September 2020, Mobius launched its initial three brands with UltraPlay; this expanded partnership will equip the company to further enhance the player experience in eSports and move forward into new regions worldwide. UltraPlay provides Mobius with cutting-edge technology and a wide range of functionalities. With its focus on sports and eSports betting, live betting, white-label and online casinos, UltraPlay was the natural choice for a turn-key platform to reach an ever-growing global audience. “We are a team of gamers at heart,” said Mobius CEO Lynn Pearce, “so when it came to deciding which eSports iGaming platform provider to partner with when launching our company, it was a no-brainer for us. We knew immediately that we wanted to partner with the multiple esports award-winning UltraPlay.” CEO Mario Ovcharov noted UltraPlay’s excitement for the new partnership as well. “Being [Mobius’s] first-choice iGaming platform provider is great recognition for the entire team of UltraPlay,” Ovcharov said. “What’s even more exciting to us is their enthusiasm and commitment to the eSports betting sector.” According to the Esports Insider, esports is no longer an accessory for gambling operators but rather a necessity (https://ibn.fm/xi1zb). While brick-and-mortar casinos and live sporting events have closed due to social distance restrictions, eSports could pivot to a fully online structure. The global eSports market is expected to reach a value of $3 billion by 2025, following its immense growth in 2020. If current trends hold, 2021 is expected to see a 10% increase in growth. This is largely due to betting operators, such as Mobius, continually improving their products and building brand loyalty (https://ibn.fm/J3Y6D). The partnership between UltraPlay and Mobius is a natural fit, one that will only improve the player experience. The iGaming professionals at UltraPlay combined with the eSports and Casino industry experts at Mobius make it possible to provide a constantly evolving, fully interactive player experience that is customer centric and endlessly entertaining under the Mobius Brand. “We strongly believe that together,” said Ovcharov, “we could further enhance the player experience in a very dynamic sector such as eSports.” Mobius provides players with access to more than 34 eSports games and mega tournaments. Available around the clock, the platform has a wide range of functionalities, mystery jackpots, cutting-edge technology, and live and prematch odds. The company has partnered with UltraPlay, a globally recognized, award-winning, unrivaled eSports odds and platform supplier. The esSports industry is booming, and Mobius is ideally positioned to see the greatest benefit from the boom. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• The global COVID pandemic, community violence and political strife have all served to batter the national psyche during the past year
• Journalists and researchers have reported rising levels of depression and anxiety as well as a rising number of people experiencing property and violent crime
• Knightscope is a company dedicated to building and marketing autonomous security robots (“ASRs”) as a means of helping to make the United States safer
• Knightscope’s ASR series comes in different models that function from a stationary base or a mobile sentry, serving as a deterrent by 24/7 presence and the technological capability to monitor, record and transmit various data streams
• Mordor Intelligence analysts forecast a favorable market for ASRs, growing at a CAGR of 7.93 percent through 2026 to a $3.91 billion market

Following a year headlined by the impositions of a deadly worldwide pandemic, community violence attributed to racial unrest and national upheaval over political strife, it comes as no surprise that researchers are reporting skyrocketing levels of anxiety and depression and feelings of insecurity in the United States (https://ibn.fm/j4QbO). Home security journalists at SafeWise noted in their second annual State of Safety report last year that 40 percent of respondents throughout the country said they’d had a personal experience with property or violent crime during the previous 12 months, a 73 percent increase over responses in 2019. Broken down between the two categories, there was a 50 percent increase in reports of experiencing violent crime and an 86 percent increase in experiencing property crime (https://ibn.fm/2jfVR). In a virtual fireside interview with IPO Edge recently, security robot innovator Knightscope CEO William Santana Li said his company’s efforts to deploy fleets of autonomous sentries in parks, parking lots and other client perimeters amounts to a personal mission to “make the United States of America the safest country in the world” (https://ibn.fm/XzaeT). In order to accomplish that goal, Knightscope has developed K series autonomous security robots (“ASRs”) that can detect and monitor a variety of information sources, whether that involves facial recognition features, license plate detection, broadcast frequency reception or thermal fluctuation discernment. The ASRs record the information they gather, including streaming video from 360-degree cameras, and can transmit the data to oversight personnel or allow overseers to monitor circumstances live and communicate with people around the robot in real time through the ASRs speakers. “If you just look at the metrics, crime has a trillion-dollar negative economic impact on the U.S. every single year. It’s a hidden tax we all pay in blood, tears and treasure,” Santana Li said. The company’s K1 stationary robot, its mobile indoor K3 model and its outdoor patrolling K5 provide a deterrent to crime simply by being present 24 hours a day, every day of the year, according to Knightscope. The robots can even serve as a safety barrier against the pandemic’s virus transmission, responding to property visitors before human interaction takes place. They also recharge their own batteries at a nearby station when power levels drop significantly, keeping them on the job and economically priced in comparison to potential human staffing costs for the same measure of service. Santana Li noted that self-driving automobiles have received the lion’s share of attention over autonomous robotic technology, but said that in building the company he felt passionately that such endeavors were not the proper way to commercialize the technology, despite his background in the automotive industry. Years after investors began pouring millions of dollars into the automobile applications, real world users are still few and far between because of the need to not only master the technology, but the real world metrics of community safety for vehicles traveling at road speeds. Knightscope’s robots, on the other hand, travel at 1 to 3 mph and serve a specific need for private companies and government clients with little or no threat of erroneously causing harm themselves. “How many people in the audience did a transport or moved something or moved themselves this week in an autonomous vehicle? Nobody, right? So $80 billion went into the sector, nobody shipped anything that’s commercially viable,” Santana Li said. “I believe Knightscope’s the only company in the world operating 24/7, 365 (days) across an entire nation, fully autonomous, no human intervention, with real-world clients and real-world environments.” Knightscope received favorable attention from the market analysts at Mordor Intelligence, who cited the K5’s usefulness as a sign that the industry’s technology is evolving. Mordor forecasts a global market for ASRs reaching $3.91 billion by 2026, indicating it expects such platforms to increase in popularity with a CAGR of 7.93 percent between now and then (https://ibn.fm/KzblF). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• XPhyto Therapeutics Corp. plans to commercialize its rapid and portable PCR Kit this year to provide point-of-care diagnostics
• The company is confident about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021
• Hugh Rogers, CEO and Director of XPhyto, revealed in the latest news release that the company will make investments and development of psychedelic treatments

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator involved in the development of new pharmaceuticals, diagnostic products, and psychedelic medicine.

As a part of its business strategy for the year 2021, the company plans to commercialize its rapid PCR kit, “the one internationally recognized standard for testing Covid-19.” This announcement was made on January 18, 2021, when the company outlined its business strategy for 2021.

XPhyto’s rapid PCR diagnostic kit, secured through a strategic German alliance with 3a-diagnostics GmbH (“3a”), is a low-cost disposable kit with a turnaround time of fewer than 30 minutes. XPhyto is positive about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021 (https://ibn.fm/cJpDM).

Why is a Rapid Testing Kit critical in controlling the COVID pandemic?

With vaccines rolling out sporadically, a rapid definitive kit could play a pivotal role in 2021 to bring the pandemic under control. PCR kits are reliable and accurate tests for Covid-19 diagnosis.

XPhyto’s quick-turnaround time makes this PCR kit well-suited for mobile and pop-up labs. It is very important as the main hurdle for covid-19 testing is the long turnaround time that ranges from 4 hours to a few weeks.

This innovation is expected to be welcomed by the government and the healthcare providers who struggle with the bottlenecks of difficult diagnostic procedures (https://ibn.fm/Irm4I).

In the same news release, Hugh Rogers, CEO and Director of XPhyto, stated that the company is geared to make continued investments and development in the arena of psychedelic medicine.

As per the statistics from the US Center for Disease Control (“CDC”), 11% of Americans have contemplated suicide since the Covid-19 outbreak. Millions of Americans and Europeans are suffering from anxiety and mental illnesses, especially amidst the coronavirus outbreak. This phenomenon has expedited the development of psychedelic compounds for the formulation of mood-improving therapeutic pharmaceutical drugs (https://ibn.fm/Uk8aW).

Professor Löbenberg, a reputed scientist and director of XPhyto Therapeutics Corp holds Health Canada licenses for research and analytical testing of a wide range of psychedelic compounds, including molecules like LSD, psilocybin, and MDMA.

In addition to Dr. Löbenberg’s drug development experience, XPhyto’s German subsidiary –Vektor Pharma TF GmbH – has globally recognized drug delivery technology and manufacturing capabilities. Prof. Dr. Thomas Beckert, managing director of Vektor Pharma TF GmbH stated that the year 2021 will be pivotal for Vektor as the company will establish itself for commercial manufacturing, pipeline development, and drug formulations for critical mental health conditions (https://ibn.fm/hhgxP).

The market intelligence firm, Data Bridge Market Research, estimated that the psychedelic pharma market could grow to almost US $7bn by 2027 (https://ibn.fm/YF7Md). Another noted Canadian investment bank, Canaccord Genuity, estimates that the budding psychedelic industry will go on to be worth US $100bn. Companies like XPhyto Therapeutics enjoy an early-mover advantage that will give an edge over business opportunities among competitors within this science-driven psychedelic era.

For a full report on XPhyto’s research and innovation for Psychedelic drugs, read the article https://ibn.fm/4WlM0.

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at  https://ibn.fm/XPHYF

• Pure Extract Technologies pursues study into psilocybin active treatments
• Study to extend for 250-day period, targeting a number of milestones
• The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor
• Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, a potential legislative movement which may soon be replicated in other jurisdictions

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has provided investors with an update in regards to its ongoing study on the formulation and manufacturing of psilocybin-based active treatments through the provision of oral tablets and capsules, as well as a nasal gel which is set to be used as an investigational product (https://ibn.fm/p8GT0).

The study, which is being carried out according to Canadian Good Manufacturing Practice as well as Good Clinical Practice, is set to focus on the formulation, manufacturing and clinical bioavailability testing of rapid onset psilocybin forms – with the latter set to be used in future efficacy clinical trials carried out by both Pure Extracts and its pharmaceutical customers.

The Company has revealed that the research study, which will extend for a 250-day period, will pursue a number of milestones, including:

• Sourcing and procurement of medicinal ingredients, excipients & packaging materials
• Raw Material Testing
• Formulation and Manufacturing Process Development, Stability Testing
• Clinical Batch Manufacturing
• Quality Control Release Testing
• Shipping of Clinical Batches to CRO

The study is scheduled to be carried out at the Toronto Institute of Pharmaceutical Technology (“TIPT”) and is set to be overseen by Dr. Alexander MacGregor, a pharmaceutical science inventor and expert in the field of pharmaceutical technology and novel drug delivery systems. Dr MacGregor has successfully applied for a wide variety of global patents in the field of medical treatments and pharmaceutical drug delivery technologies, with his various innovations resulting in ground-breaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections and post-operative pain.

“We are excited about the R&D progress we are going to make with TIPT over the next 6 – 8 months while waiting to receive our Dealer’s License from Health Canada,” commented Pure Extracts’ CEO Ben Nikolaevsky regarding the study and tie-up with the TIPT. “We will be well prepared for our move into the controlled substances world of psychedelics and will have advanced knowledge regarding psilocybin and its associated novel delivery mechanisms.”

While psychedelics continue to be classified as a controlled substance in Canada, officials in the Canadian Government stated in November of 2020 – in response to an earlier petition tabled in Parliament – that there were still avenues whereby certain individuals could gain exemptions to legally consume them.

The group behind the petition, the Canadian Psychedelic Association (https://ibn.fm/fDyBC), said when the petition was originally read before Parliament in September that entheogenic medicines “could be the crucial missing piece in healing epidemic rates of depression, anxiety, PTSD, and drug addiction while empowering people to realize greater wholeness, purpose and connection.”

Nonetheless, the Canadian Government’s statement came only shortly after U.S. voters approved a measure to decriminalize the possession of plant-and fungi-based entheogenic substances, while voters in Oregon went further still – passing a reform initiative seeking to legalize psilocybin mushrooms for therapeutic use (https://ibn.fm/K3mqh).

Through its ongoing study delving into psilocybin based active treatments, Pure Extracts is now seeking to be at the very forefront of the product development curve should Canadian governmental authorities opt to legalize the use of psychedelics and psilocybin mushrooms in the coming future.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• As host to B. Riley’s Securities’ 2021 Vision Day, SRAX offers event content to Sequire community
• SRAX CEO states that B. Riley event is “perfect example of our growing Virtual Event Platform capabilities”
• Definitive agreement between SRAX-created BIGtoken, FPVD closes

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, concluded its role as the exclusive technology host for B. Riley Securities’ 2021 Vision Day (https://ibn.fm/D7R3c); sessions from the event are available exclusively to B. Riley clients and investors on the Sequire platform. The company also announced that its BIGtoken platform closed on its share exchange agreement with Force Protection Video Equipment Corporation (OTC: FPVD), making BIG a public company through the reverse merger transaction (https://ibn.fm/ir6ii). The prestigious B. Riley Vision Day event was held on the Sequire Virtual Events platform, thereby allowing the Sequire community privileged access to sessions and content. The daylong virtual investor conference included video presentations and fireside chats discussing the top stock picks from B. Riley’s award-winning equity research team. All the sessions are available exclusively to B. Riley clients and investors who register at BRiley.mysequire.com. “We were honored to have been selected by B. Riley Securities to host its 2021 Vision Day event, following our success with the LD Micro Main Event in December,” said SRAX founder and CEO Christopher Miglino. “This event is a perfect example of our growing Virtual Event Platform capabilities. We were pleased to work with the B. Riley team and contribute to another successful event. Other big news for SRAX is the closing of the previously announced share exchange transaction between SRAX-created BIGtoken and Force Protection Video Equipment Corporation (OTC: FPVD). Initially announced on Sept. 30, 2020, the definite agreement outlined plans for SRAX to receive 88.9% of the issued and outstanding shares of FPVD in exchange for 100% of the shares of BIGtoken. The agreement also noted that upon completion of the transaction, FPVD would be renamed BIGtoken with Lou Kerner appointed CEO (https://ibn.fm/Z2Sa3). “Lou has been working with data and internet startups his entire career,” said Miglino. “He has a detailed understanding of Blockchain and how it is applied to augment business applications. Blockchain will play a big part in the future of consumer identity and privacy, and we have a shared vision with Lou on what this will look like. Not only is Lou a technology expert, but his knowledge of the capital markets will be a significant asset to BIGtoken as the company is uplisted to a nationally listed exchange.” SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 3 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Most recent tests show MustGrow’s patented biopesticide achieved 100% control over Aphanomyces within 24 hours
• Plant-based biopesticide uses natural defense mechanism found in mustard seed to control diseases, pests and weeds
• MustGrow hoping to provide valuable crop-protection tool for pulse-crop farmers

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide has achieved 100% control of root-rot disease in a recent round of laboratory tests (https://ibn.fm/WJo4p). MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, is focused on providing natural, science-based biological solutions to replace synthetic chemicals in the cultivation process. MustGrow’s safe and effective organic biopesticide is plant based; it uses a natural defense mechanism found in the mustard seed to control diseases, pests and weeds. In a recent round of tests, which were conducted by an independent third-party lab, MustGrow’s patented mustard-derived biopesticide achieved 100% control over Aphanomyces euteiches zoospores (Aphanomyces) within 24 hours and at economic application rates. “It is great to see MustGrow’s mustard plant-based biopesticide continue to perform, particularly with 100% disease control measured at exceptionally low application rates,” said MustGrow COO Colin Bletsky. “The level of control of hard-to-kill diseases we continue to achieve combined with the beneficial properties of our product for soil health provide a great opportunity for improved yields for farmers and a more robust food supply. I am very hopeful that we can potentially provide a valuable crop-protection tool for pulse crop farmers.” Aphanomyces is a soil-borne, root-rot disease that destroys peas, lentils and legume crops, commonly referred to as pulse crops. In infected fields, the disease can result in yield losses ranging from 10% to 100% complete destruction. The ability to control the disease using an organic, plant-based biopesticide could have a significant impact on the harvests of farmers seeking to eradicate the disease. For instance, in 2019 Canada produced 9.2 million tons of pulse crops, making it one of the world’s largest producers. One study reported that Aphanomyces caused $20 million in annual pulse crop losses in Canada and $100 million worldwide. Currently the only available treatments slow down the spread in an attempt to reduce the severity of the disease; no treatments exist that control the devastating root-rot plague. MustGrow’s plant-based biopesticide aims to change that. With the most recent lab results in, MustGrow is now looking forward to evaluating its proprietary product in larger-scale greenhouse and field tests. MustGrow’s biopesticide is applied to the soil before crops are planted. The greenhouse and field tests are a significant step forward in the progression and preparation of the product for commercial use and application. This agriculture biotech company, which is focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, appears poised to leverage the growing momentum favoring alternatives to synthetic chemicals. As global agriculture looks to move closer to sustainable ways of boosting yields and crop protection, MustGrow continues to position itself as an essential part of the food landscape of the future with its mustard plant-based biopesticide. For more information, visit the company’s website at www.MustGrow.ca. NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Customers seek out highly personalized buying experiences in 2020 and beyond.
• Companies looking at what it means to be customer centric, how to create long-lasting relationships.
• Highly personalized customer service has always been high priority for SHRG.

As a new year begins, direct-selling leaders are looking to the future and wondering what trends will stick following the COVID-19 pandemic. Industry experts predict that companies with a strong customer-centric focus will perform the best moving forward, a prediction that bodes well for Sharing Services Global Corporation (OTCQB: SHRG). Sharing Services is committed to elevating the convenience and value of doing business for both its growing customer base and dedicated distributors. “The organizations that will perform the best through this period and beyond will be those that maintain a strong customer-centric focus while dealing with the complexity, uncertainty and risk that cloud the business landscape,” reported a recent “Direct-Selling News” article (https://ibn.fm/dEGMv). “This means knowing the sources of risk and opportunity within the global customer base. It means finding new routes to reaching customers—increasingly, through channels that customers control. And it means focusing less on driving customer transactions for short-term gain, and more on fostering trust-based relationships over the long term.” With that in mind, many companies are looking closely at what it means to be customer centric and how to create long-lasting relationships rather than short-term transactions. The rise of using digital tools instead of in-person sales was a necessity during the pandemic, but a convenience that may just stick around. Customers are seeking out tools that personalize their experience online. Add to this the rise of a gig economy, and the direct sales industry is experiencing massive growth. These are all priorities — and areas of expertise — for Sharing Services. SHRG markets and distributes health and wellness products under the Elevacity brand through an independent sales force of distributors called Elepreneurs. The company is committed to elevating customers’ and distributors’ lives through products, services and training opportunities. Sharing Services’ opportunity features a complete virtual business, including a phone app, web system and automated free sampling program — all designed to make it easier than ever before for SHRG Elepreneurs to focus on consumers. Customer centrism begins at home, observes the “Direct-Selling News” article. It starts on the front line with the distributors. Once the home front understands the value proposition of the company, sharing that message becomes second nature. SHRG executives have long credited the company’s success to its Elepreneurs, who are on the frontlines of the company and who continue to generate 100% organic growth. Through these entrepreneurs’ dedication to providing personalized customer experiences, customer retention has increased and capturing new markets has been achievable. Sharing Services Global Corporation is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Sharing Services has two primary divisions: Elevacity(R) Holdings LLC, the parent company of Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC, the parent company of wholly owned subsidiary Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line. For more information, visit the company’s website at www.SHRGInc.com NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas
• Glioblastomas are a class of aggressive brain cancers with no known cure and a median life expectancy of 14 to 16 months following diagnosis
• The FDA’s decision to grant CNSP’s request for IND status clears the way for the company to begin human clinical trials within the next couple of months
• The company’s sublicensee partner, WPD Pharmaceuticals, will also prepare a first-ever Phase I trial for drug safety in children, planned later this year in Poland

During the last year the COVID-19 pandemic has occupied large headlines worldwide while small neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) has been quietly building a newsworthy effort of its own to improve a select group of individuals’ lives, preparing to launch medical trials that could help end the unrelenting and ultimately fatal advance of glioblastoma brain cancers. CNSP acquired the worldwide exclusive licensing to its leading drug candidate Berubicin, an anthracycline that has demonstrated its potential in fighting off glioblastomas and a stand-out drug among other anthracyclines because of its apparent ability to effectively cross the blood-brain barrier and target central nervous system malignancies. In a January podcast interview, company CEO John Climaco showed his excitement at news the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status, clearing the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials. … We have five employees at this company, so we are a tiny little shop. But we have an absolute powerhouse compound.” The podcast, co-hosted by Sid Vaidya and Eric Gershey, is available for on-demand listening at https://anchor.fm/c3chat. Berubicin’s “powerhouse” potential was demonstrated in an initial Phase 1 trial completed by another company well over a decade ago. Within the very limited pool of participants in the trial, 44 percent saw their disease stabilize or even begin to improve. One patient emerged cancer-free and as of the most recent medical assessment last year was still alive and still in remission 14 years after the Phase 1 trial — a remarkable exception to the rule that the vast majority of glioblastoma patients will be dead within 14 to 16 months of diagnosis. CNSP’s planned Phase 2 trials will use a much larger pool of 243 patients for its real-time comparison of Berubicin’s performance against the “standard of care” chemotherapy drug lomustine in side-by-side brackets that compare the 162 Berubicin users with 81 lomustine users. The trials will take place in about 60 research centers scattered across North America, Europe and the Asia-Pacific region to help deliver a diverse representation of individuals (https://ibn.fm/4sWQi). While the adult trials are taking place, CNSP’s sublicensee partner for testing will also be preparing a first-ever Phase I trial for drug safety in children who have glioblastomas and have already failed to see a significant turnaround with standard-of-care medications. The pediatric trial is slated to begin later in the year in Poland. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP